Cardiovascular safety of zoledronic acid in the treatment of primary osteoporosis: A meta-analysis and systematic review
Pooled result · Cardiovascular eventsResult — go to the resultRelative risk 1.15 95 % CI 1.05–1.26Authors' conclusion
In women with primary osteoporosis, zoledronic acid may increase the risk of atrial fibrillation (P = 0.06) and arrhythmias (P = 0.001) compared with placebo, independent of the risk of major adverse cardiovascular events, angina, and heart failure.
Study context
- Population
- Patients with primary osteoporosis in randomized controlled trials (RCTs) of zoledronic acid vs placebo9 RCTs
- Comparison
- Zoledronic acid vs placebo
- Outcome
- Cardiovascular events (cardiovascular safety)
Methodological detailsPRISMA
- PRISMA
Pooled result
Cardiovascular events
Relative risk
1.15
95 % CI 1.05–1.26
P = 0.002
Zoledronic acidvs Placebo
RR 1.15 (95 % CI 1.05–1.26); P = 0.002
As reported in the abstract
Safety
| Outcome | RR (95 % CI) | P value | |
|---|---|---|---|
| CV eventsI2=12 % | 1.15 (1.05–1.26) | P = 0.002 | |
| 0.512Relative risk (log scale) |
- CV events: 9 RCTs
AF
- RR, zoledronic acid vs placebo
- 1.21 (95 % CI 0.99-1.47, I2=0 %, P = 0.06)
Arrhythmia
- RR, zoledronic acid vs placebo
- 1.30 (95 % CI 1.11-1.52, I2=34 %, P = 0.001)
Original publication
Cardiovascular safety of zoledronic acid in the treatment of primary osteoporosis: A meta-analysis and systematic review. Semin Arthritis Rheum. Published 8 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →